Disease Landscape and Forecast Insights

Crohn’s disease (CD) and ulcerative colitis (UC) are the two gastrointestinal inflammatory disorders that constitute inflammatory bowel disease (IBD), affecting approximately 1.25 million people…

For the estimated 700,000 people in the United States who suffer from Crohn’s disease (CD), there are multiple prescription therapies that are available for treating the associated symptoms. The…

LaunchTrends: Entyvio Wave 3 (US) measures the impact of this novel agent on the moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD) market one year following launch. The report…

The TreatmentTrends Crohn’s Disease and Ulcerative Colitis (EU) report explores current trends in the management of CD and UC from the perspective of 250 treating EU5 gastroenterologists. The…

Are new drug classes expected to address the considerable unmet need? Crohn’s disease (CD) is a chronic gastrointestinal inflammatory disorder affecting over 1 million people in the major…

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…

Treatment options for the estimated 700,000 people in the United States, who suffer from Crohn’s disease (CD), include multiple conventional, largely generic small molecules and more-potent…

Last Updated 29 September 2014 Treatment options for Crohn’s disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis…

Takeda’s Entyvio (vedolizumab) gained FDA approval in May 2014; the drug launched in the United States in June 2014. This report measures the impact of this novel agent on the moderate to severe…

Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…

Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/…

Physicians Would Welcome Therapies Causing Lower Rate of Serious Infections than Remicade, but Will Payers View Such Agents Favorably? Treatment for Crohn’s disease (CD)—a relapsing/…